Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon, with a price target of $9.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Terence Flynn has given his Hold rating due to a combination of factors including a mixed fundamental picture and unresolved governance questions. Organon’s initial 2026 outlook is slightly ahead of market expectations on both revenue and EBITDA, but the recent quarter fell short in Women’s Health, and the stock has lagged the broader market amid uncertainty around an ongoing CEO search.
At the same time, management is guiding to near-term margin pressure from foreign-exchange effects and inventory dynamics, with only gradual improvement expected as cost efficiencies and the Merck manufacturing separation benefit margins over time. The newly announced review of past biosimilar purchases by the Audit Committee adds another layer of risk, leaving Flynn inclined to wait for clearer visibility on earnings quality and leadership before adopting a more decisive positive or negative stance.
In another report released on February 4, TipRanks – Google also reiterated a Hold rating on the stock with a $8.00 price target.
OGN’s price has also changed moderately for the past six months – from $9.360 to $7.390, which is a -21.05% drop .